XenoPort (XNPT) reported quarterly earnings results on Thursday, May-5-2016. The company reported $-0.23 earnings per share for the quarter, missing the analyst consensus estimate by $-0.01. Analysts had a consensus of $-0.22. The company posted revenue of $14.12 million in the period, compared to analysts expectations of $14.06 million. The company’s revenue was up 99.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.33 EPS.
XenoPort closed down -0.08 points or -1.86% at $4.21 with 2,95,634 shares getting traded on Wednesday. Post opening the session at $4.3, the shares hit an intraday low of $4.16 and an intraday high of $4.31 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Nov 13, 2015, John Gordon Freund (director) sold 909 shares at $6.68 per share price. According to the SEC, on Sep 2, 2015, Ronald W Barrett (Chief Executive Officer) sold 12,500 shares at $7.00 per share price. On May 12, 2015, Wendall Wierenga (director) purchased 5,000 shares at $5.63 per share price, according to the Form-4 filing with the securities and exchange commission.
XenoPort Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the treatment of neurological and other disorders. The Company is commercializing HORIZANT (gabapentin enacarbil) Extended-Release Tablets in the United States and REGNITE (gabapentin enacarbil) Extended-Release Tablets is being marketed in Japan by Astellas Pharma Inc. (Astellas). The Company’s development-stage product candidates include XP23829 a fumaric acid ester product candidate XP21279 and arbaclofin placarbil (AP). HORIZANT is used for the treatment of primary restless legs syndrome (RLS) and for the management of postherpetic neuralgia (PHN). XP23829 is a fumaric acid ester compound and a prodrug of monomethyl fumarate (MMF) which has completed Phase I clinical trials. XP21279 is a transported prodrug of levodopa for the treatment of patients with idiopathic Parkinson’s disease and has completed Phase II clinical trials.